The study randomized 453 patients with stage II–IIIA NSCLC without EGFR mutations or ALK fusions to receive 3–4 cycles of tislelizumab or placebo in combination with platinum-based chemotherapy followed by surgery and eight cycles of adjuvant tislelizumab or placebo. Here, ALK is linked to non-small cell lung carcinoma.